Assenagon Asset Management S.A. I Mab Transaction History

Assenagon Asset Management S.A.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 27, 2022	SELL	$8.27 - $18.43 $2.35 Million - $5.24 Million	-284,260 Reduced 38.05%	462,867 $5.23 Million
Q1 2022 Apr 25, 2022	BUY	$12.54 - $46.93 $5.08 Million - $19 Million	405,497 Added 118.69%	747,127 $12.1 Million
Q4 2021 Feb 01, 2022	BUY	$45.28 - $74.5 $7.3 Million - $12 Million	161,131 Added 89.27%	341,630 $16.2 Million
Q3 2021 Oct 19, 2021	BUY	$57.18 - $84.43 $5.55 Million - $8.2 Million	97,109 Added 116.45%	180,499 $13.1 Million
Q2 2021 Jul 15, 2021	BUY	$47.86 - $83.95 $3.99 Million - $7 Million	83,390 New	83,390 $7 Million

16M

11.9K

3.5K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $130M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

Stay updated on Assenagon Asset Management S.A. with notifications on news.